title: [Bisphosphonate or Raloxifene?: which drug we can choose for osteoporotic patients?].
abstract: Raloxifene is preferred because of free from empty stomach and amelioration of lipid metabolism in spite of the significant effect of bisphosphonate on BMD and metabolic markers. As compliance is essential for the prevention of fracture, physicians should discuss about the treatment with their patients. There are no scientific evidences which drug is more suitable to osteoporotic patients. Therefore, bisphosphonate is recommended to the patients with severe osteoporosis, recognition of the disease, and/or expectation for the prevention of hip fracture by the treatment, on the condition that patients are not vitamin D deficiency. Raloxifene is recommended to the patients with mild osteoporosis, poor recognition of the disease, and/or low risk of the new fracture (s). The hyperlipidemic patients with osteoporosis are another candidates for raloxifene.
authors.affiliation: Geriatric Medicine, Postgraduate School of Medicine, Osaka City University Medical School.
authors.forename: Takami
authors.initials: T
authors.lastname: Miki
authors.forename: Shinichi
authors.initials: S
authors.lastname: Saito
mesh_terms: D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D020849:Raloxifene Hydrochloride